Rate My Professor Anne Talkington

Anne Talkington is an Assistant Professor in the Department of Pharmaceutical Sciences within the School of Pharmacy and Pharmaceutical Sciences at the University at Buffalo, where she joined the faculty in fall 2023 as part of the university's Advancing Top 25 faculty hiring initiative. Prior to her appointment, she conducted postdoctoral research in systems immunology in the Department of Biomedical Engineering at the University of Virginia, focusing on tumor-immune interactions in the melanoma tumor microenvironment using patient omics data. She also completed a National Research Council Research Associateship Award fellowship at the National Institute of Standards and Technology, modeling tumor-immune dynamics and systemic drug delivery strategies to enhance cancer immunotherapies. Talkington holds a double major in mathematics and biology from Duke University, a master's degree in mathematics from the University of North Carolina at Chapel Hill, and a PhD in computational biology from the same institution.

Her research centers on computational and mathematical modeling of biological systems, with applications in therapeutic optimization, drug delivery, pharmacokinetics, pharmacodynamics, and cancer immunology. Talkington develops physiologically based pharmacokinetic models, multiscale models for immune checkpoint blockade optimization, and investigates anti-PEG antibody effects on nanomedicine clearance. Notable publications include 'Estimating tumor growth rates in vivo' (Bulletin of Mathematical Biology, 2015), 'Ordinary differential equation models for adoptive immunotherapy' (Bulletin of Mathematical Biology, 2018), 'A PBPK model recapitulates early kinetics of anti-PEG antibody-mediated clearance of PEG-liposomes' (Journal of Controlled Release, 2022), 'Uncovering Cellular Interactome Drivers of Immune Checkpoint Inhibitor Response in Advanced Melanoma Patients' (Cellular and Molecular Bioengineering, 2025), and 'Opportunities for machine learning and artificial intelligence in physiologically-based pharmacokinetic (PBPK) modeling' (Advanced Drug Delivery Reviews, 2025). At UB, she is affiliated with the Institute for Artificial Intelligence and Data Science, contributes to the Drug Discovery, Development and Evaluation Hub, serves as co-investigator on the Center for Protein Therapeutics, advises graduate students on thesis committees, and presents seminars such as the IAD Tech Exchange Seminar Series.